Infective Endocarditis in the 21st Century

Login or register to view PDF.
Abstract

Infective endocarditis (IE) continues to be a disease characterized by high mortality and morbidity that has not been affected by significant advances in the last century. Despite considerable improvements in diagnosis and medical and surgical therapy, mortality has remained high for the past 25 years, in contrast to the majority of cardiovascular diseases such as heart failure and acute coronary syndromes, which have demonstrated noticeable improvements in terms of prognosis. IE has an exceptionally varied clinical presentation, from a severely ill patient with symptoms of acute infection and sepsis to an apparently healthy individual with only occasional night sweats, weight loss, and low-grade fever. Clinical manifestations of IE can be caused by symptoms or complications of the infection or by its frequent non-infectious complications, such as vascular and immunologic phenomena. IE remains a deadly disease, frequently associated with a difficult diagnosis. Significant changes in epidemiology and microbiology have increased the differences between patients seen in the US and Europe and those in countries with a higher incidence of rheumatic heart disease, such as South America and India. Therefore, specific regional approaches to IE are necessary.

Disclosure
The authors have no conflicts of interest to declare.
Correspondence
Antonio Carlos Palandri Chagas, MD, Heart Institute, University of São Paulo, Av Enéas de Carvalho Aguiar, 44, 05403-000 – São Paulo, Brazil. E: antonio.chagas@incor.usp.br
Received date
10 June 2010
Accepted date
20 July 2010
DOI
https://doi.org/10.15420/usc.2010.7.2.61

Infective endocarditis (IE) continues to be a disease characterized by high mortality and morbidity that has not been affected by significant advances in the last century. Despite considerable improvements in diagnosis and medical and surgical therapy, mortality has remained high for the past 25 years, in contrast to the majority of cardiovascular diseases such as heart failure and acute coronary syndromes, which have demonstrated noticeable improvements in terms of prognosis. The current in-hospital mortality for patients with IE is 15–20%, with one-year mortality approaching 40%. In a 16-year follow-up of patients discharged with the diagnosis of IE, only 5% of the patients remained alive free of a new episode of endocarditis and without valve replacement surgery.

As with most valvular heart diseases, studies of IE in the literature are mainly series of reports and/or case studies; there is a marked absence of prospective controlled studies on this disease, perhaps because of its relative rarity and clinical polymorphism. The only multicentric prospective registry of IE is the International Collaboration on Endocarditis–Prospective Cohort Study (ICE-PCS), in which 58 hospitals from 25 countries took part.

The purpose of this article is to review the epidemiology of IE, modern therapy, both clinical and surgical, and to discuss the need for IE prophylaxis.

A Difficult Diagnosis

Endocarditis has an exceptionally varied clinical presentation, from a severely ill patient with symptoms of acute infection and sepsis to an apparently healthy individual with only occasional night sweats, weight loss, and low-grade fever. Clinical manifestations in IE can be caused by symptoms or complications of the infection or by its frequent non-infectious complications, such as vascular and immunologic phenomena. Immunologic symptoms such as arthritis and glomerulonephritis are especially frequent because of the high quantity of circulating immunocomplexes in IE. Vascular complications such as mycotic aneurysms and septic emboli can lead to neurologic or peripheral symptoms as the initial manifestation of the disease.

IE is a great deceiver, mimicking several rheumatologic, hematologic, neurologic, and nephrologic diseases. Quite frequently, patients with suspected IE are referred from other specialists in internal medicine. In particular, the patient is quite frequently first seen by a rheumatologist because of arthritis, fever, high acute-phase proteins, and frequently a positive rheumatoid factor. This polymorphic presentation frequently leads to delays in the diagnosis of IE. In a study at our institution, The Heart Institute – University of São Paulo, the duration of symptoms until the diagnosis of IE was 49.6±64.5 days.2

In 1994, Durack and et al.3 proposed diagnostic criteria for IE, initially conceived to classify the complex clinical manifestations and findings in IE for scientific study purposes. These criteria were rapidly implemented in clinical practice, becoming widely known as the Duke criteria (see Table 1). These were the first criteria to include echocardiography as a morphologic parameter, significantly improving sensitivity and maintaining the same specificity as the previous criteria.

The Duke criteria characterize the probability of IE as ‘definite,’ ‘possible,’ or ‘excluded.’ The main criteria are identification of the causative organism and echocardiographic demonstration of endocardial involvement. Additional criteria include fever, vascular involvement, or a predisposing heart disease. Since the initial publication of the Duke criteria, several modifications have been proposed with the purpose of increasing their sensitivity. The extended Duke criteria of Li et al.4 are now generally accepted: these consider Staphylococcus aureus bacteremia to be a main criterion, as a positive blood culture for S. aureus is associated with endovascular infection in up to 15% of cases. However, whenever new parameters are introduced it must be kept in mind that increased sensitivity often comes at the price of diminished specificity. Thus, a current meta-analysis of 3,557 patients has shown that the rise in sensitivity brought about by the Li modifications is associated with a similar fall in specificity.5

In summary, diagnostic criteria are not a substitute for rational clinical judgment, particularly when blood cultures are negative, when prosthetic valves or pacemaker electrodes are infected, or in the case of right-side endocarditis.

Changes in Patient Characteristics of Infective Endocarditis—A Widening Gap

Geographic differences in the epidemiology of IE are becoming more evident. In developing countries, due to the high incidence of rheumatic fever and poor dental care, IE is still a subacute or chronic disease occurring primarily in younger patients with rheumatic valvular abnormalities. In stark contrast, IE is changing rapidly in the US and Europe, presenting few of the classic clinical findings traditionally associated with IE. Forty years ago, approximately 50% of cases of IE in the US were superimposed on pre-existing rheumatic lesions6 compared with <5% in recent studies, with prosthetic valve endocarditis (PVE) detectable in one-fifth of patients.7

An emerging population at risk for IE in developed countries consists of patients with healthcare-associated infections. Overall, IE was attributed to a healthcare-related exposure in nearly 25% of the patients. These findings confirm those of recent reports from small single-center studies8,9 and provide evidence that these population changes are occurring in many regions of the world. Thus, nosocomial endocarditis is on the rise in the developed world, while poor nations retain the classic profile of IE.

Changes in Infective Agents

Changes in the epidemiology of endocarditis in the developed world led to a change in infecting micro-organisms. While in South America, India, and South-East Asia endocarditis is still predominantly caused by Streptococci10 and linked to poor oral health, S. aureus is now the most common cause of IE in the developed world.11–13 This shift is due in part to the global presence of risk factors for S. aureus-associated IE (i.e. intravenous drug use, healthcare contact, and invasive procedures). Given the growing antimicrobial resistance of S. aureus,14 including to vancomycin,15,16 the importance of this pathogen as a potentially lethal infection is a cause of concern.,br> As the population of the developed world grows older, there is a higher prevalence of S. bovis-associated IE, mainly in Europe.1 Recent trends also pointed to the fact that HACEK-associated IE was relatively uncommon in North America, and that most cases of Q fever and Bartonella-associated IE came from Europe. Whether these findings reflect differences in patient characteristics, regional healthcare access, diagnostic bias, or other factors is still to be determined.

These changes in patients and pathogens have important implications for the diagnosis and management of IE. As nosocomial endocarditis is on the rise, stricter measures for prevention of bloodstream infections must be enforced in hospitals. Elderly hospitalized patients must have careful diagnostic attention in the presence of fever and bacteremia.

Meanwhile, in the developing world, in addition to the rise in hospital-related endocarditis, streptococcal endocarditis related to poor oral hygiene and lack of access to dental care in rheumatic patients is still very much the case. Improvements in access to medical and dental care, associated with aggressive primary prophylaxis of rheumatic fever, have the potential to markedly reduce the incidence of IE in developing countries.

Treatment—Principles and Practice

The fundamental goal of therapy in IE is the eradication of the pathogen from the infected tissue. There are several specific and non-specific defense mechanisms of micro-organisms, such as biofilm formation and increasing tolerance or resistance to various antibiotics, which make IE a particularly difficult-to-treat infection, requiring long courses of high-dose intravenous antibiotics. Generally, native-valve endocarditis must be treated for a four-week period and prosthetic valve endocarditis must be treated for at least six weeks, if not longer.

Although most previously published guidelines indicated combination therapy with beta-lactams and gentamicin, this recommendation has recently been questioned in literature, particularly in terms of the treatment of staphylococcal infections. The benefit of aminoglycosides was seen in small randomized trials more than 20 years ago, showing that the combination of nafcillin and gentamicin led to a more rapid defervescence in IE patients. Recent meta-analyses show that the combination therapy with gentamicin is not clinically superior to beta-lactam monotherapy17,18 and may be nephrotoxic. In the American Heart Association (AHA) guideline,19 combination therapy with gentamicin is designated as optional for the treatment of staphylococcal infection. This contrasts with the finding from a Swedish registry that the survival of patients with culture-negative IE is significantly improved if they are given combination therapy with gentamicin.20

As staphylococcal endocarditis is on the rise in Europe and the US, antistaphylococcal agents other than vancominin are being studied. The lipopeptide daptomycin, for example, has been studied in a prospective, randomized trial in patients with right-heart endocarditis and has been approved for this indication.21 The most interesting discovery is that this agent, unlike vancomycin, was at least as effective as the combination of a beta-lactam antibiotic and gentamicin in the treatment of methicillin-resistant staphylococcal infection.

Daptomycin was significantly less nephrotoxic than a combination of vancomycin or a semi-synthetic penicillin with gentamicin. Daptomycin was found to elevate the serum creatine kinase (CK) concentration; therefore, the latter should be monitored when daptomycin is given. In a small number of cases in this study, the minimal inhibitory concentration (MIC) of daptomycin was found to rise under treatment. Although this finding is of uncertain significance, it indicates the possible development of resistance and thus requires further careful evaluation.21 The oxazolidinone linezolide has also been used successfully in a number of cases of staphylococcal IE,22 but as yet there are no prospective data on this form of treatment.

Is There a Low-risk Group in Infective Endocarditis?

Based on expert opinion only, the AHA recently changed the guidelines for the prevention of IE23 on the assumption that there may be a ‘benign’ group, even if the existence of this group has never been demonstrated. Multinational surveys of IE demonstrate a consistently high intrahospital mortality of approximately 20%. Even in groups with higher incidence of the so-called ‘low-risk’ endocarditis—that is, streptococcal endocarditis of a native valve in young patients (the most common cases in the developing world)—the mortality rate remains 18–30%.10 The decrease in the incidence of streptococcal endocarditis in Europe and North America led to the false impression that this group is less affected and has a lower IE risk. The fact remains that in developing countries, where streptococcal disease is frequent, all patients with IE have a disease with high morbidity and mortality, even young rheumatic patients.

If the AHA were certain of the inefficacy of the prophylactic regimen for IE, it might well have stated that there is no indication for prophylaxis in any population. As the AHA chose to maintain prophylaxis in the ‘high-risk’ group, the opinion is that prophylaxis may still be of some benefit. In our view, the high-risk group encompasses all patients with IE, not only those with manifestations that are frequent in North America and Europe (i.e. prosthetic valve endocarditis and endocarditis in congenital heart disease). Thus, we chose to remain adherent to the older AHA guidelines,24 and we do recommend prophylaxis for all patients, including young rheumatic patients with native valves; however, for young rheumatic patients the maintenance of good oral health and access to dental care are more important than IE prophylaxis.

The ICE–Merged Database (ICE-MD) and ICE-PCS, the largest ever in IE, found several factors that were independently associated with in-hospital mortality. Some of these factors are clinical, such as increasing age, presence of pulmonary edema, and paravalvular complications. In addition, prosthetic valve IE and staphylococcal IE were associated with an increased risk for in-hospital death, whereas there was a decreased risk associated with viridans streptococcal IE. An elevated erythrocyte sedimentation rate (ESR) was associated with a decreased risk for death, although the reason for this is unclear. Elevated ESR may be associated with more chronic infection, thereby signifying a more chronic clinical course.

Trends in Cardiac Surgery in Infective Endocarditis and Prosthetic Valve Endocarditis

In the ICE-PCS nearly 50% of patients had surgery, which indicates that the threshold for early surgical treatment has lowered. In other surveys of IE outside the US and Europe, 35% of patients required surgery.10 This may reflect the higher incidence of streptococcal endocarditis, which is less frequently related to the need for surgery. The ICE-PCS study has found that early surgery is critical in improving survival in patients with definite IE. This finding adds detail to recent reports supporting early surgical intervention25,26 and adds credibility to the practice of a combined medical and surgical approach from admission for patients with IE, specifically in those with congestive heart failure and prosthetic valve infections.

Despite improvements in clinical and surgical therapy, PVE carries a high mortality risk ranging from 20 to 80% of affected patients.27 PVE is still associated with a more difficult diagnosis, a more severe prognosis, and difficulties in therapeutic strategies. Both mechanical and bioprosthetic valves can be involved by the infection, and their rate of infection is similar at five years (5.7%). However, mechanical prosthetic valves seem to carry a higher risk for infection during the first three months.28 Several factors have been associated with bad prognosis in PVE, including age, staphylococcal infection, early PVE, congestive heart failure, stroke, and intracardiac abscess. Among them, complicated PVE and staphylococcal infections are the most powerful markers.29

The best therapeutic option in PVE is still being discussed. Although a medical surgical strategy is said to represent the best therapeutic option,30 medical therapy can be sufficient in some patients.31 Although surgery is considered the best option when PVE causes severe prosthetic dysfunction or heart failure, current recommendations24,32 are not based on prospective randomized studies, and the best therapy for PVE in the absence of such complications is still debated. Surprisingly, surgery was performed in only 50% of patients with PVE in the Euro Heart Survey,32 similar to the rate for patients with NVE.

Conclusion

In conclusion, IE remains a deadly disease, frequently associated with a difficult and tricky diagnosis. Significant changes in epidemiology and microbiology have increased differences between patients seen in the US and Europe and those in countries with a higher incidence of rheumatic heart disease, such as South America and India. Therefore, specific regional approaches to IE are necessary.

References
  1. Murdoch DR, Corey R, Hoen B, et al., Clinical Presentation, Etiology, and Outcome of Infective Endocarditis in the 21st Century The International Collaboration on Endocarditis– Prospective Cohort Study, Arch Intern Med, 2009;169(5):463–73.
    Crossref | PubMed
  2. Issa VS, Fabri J Jr, Pomerantzeff PMA, et al., Duration of symptoms in infective endocarditis, Int Heart J, 2003;89:63–70.
    Crossref | PubMed
  3. Durack DT, Lukes AS, Bright DK, New criteria for diagnosis of infective endocarditis: utilization of specific echocardiographic findings. Duke Endocarditis Service, Am J Med, 1994;96:200–209.
    Crossref | PubMed
  4. Li JS, Sexton DJ, Mick N, et al., Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis, Clin Infect Dis, 2000;30:633–8.
    Crossref | PubMed
  5. Neuerburg CK, Breuckmann F, Buhr C, et al., Duke-Kriterien zur Diagnostik der infektiösen Endokarditis: Metaanalyse von 3557 Fällen und Ergebnisse eine prospektiven Studie (Abstract), Clin Res Cardiol, 2007;(Suppl. 1):V1148.
  6. Weinstein L, Rubin RH, Infective endocarditis: 1973, Prog Cardiovasc Dis, 1973;16(3):239–74.
    Crossref | PubMed
  7. Wang A, Athan P, Pappas PA, Contemporary Clinical Profile and Outcome of Prosthetic Valve Endocarditis, JAMA, 2007:297:1354.
    Crossref | PubMed
  8. Cabell CH, Jollis JG, Peterson GE, et al., Changing patient characteristics and the effect on mortality in endocarditis, Arch Intern Med, 2002;162(1):90–94.
    Crossref | PubMed
  9. Spies C, Madison JR, Schatz IJ, Infective endocarditis in patients with endstage renal disease: clinical presentation and outcome, Arch Intern Med, 2004;164(1):71–5.
    Crossref | PubMed
  10. Mansur AJ, Dal Bó C, Fukushima JT, et al., Relapses, recurrences, valve replacements, and mortality during the long-term follow-up after infective endocarditis, Am Heart J, 2001;141:78–86.
    Crossref | PubMed
  11. Hoen B, Alla F, Selton-Suty C, et al., Association pour l’Etude et la Pre´vention del’Endocardite Infectieuse (AEPEI) Study Group. Changing profile of infective endocarditis:results of a 1-year survey in France, JAMA, 2002;288(1):75–81.
    Crossref
  12. Mullany CJ, Chua YL, Schaff HV, et al., Early and late survival after surgical treatment of culture-positive active endocarditis, Mayo Clin Proc, 1995;70(6):517–25.
    Crossref | PubMed
  13. Sanabria TJ, Alpert JS, Goldberg R, et al., Increasing frequency of staphylococcal infective endocarditis: experience at a university hospital, 1981 through 1988, Arch Intern Med, 1990;150(6):1305–9.
    Crossref | PubMed
  14. Naimi TS, LeDell KH, Como-Sabetti K, et al., Comparison of community- and health care–associated methicillin-resistant Staphylococcus aureus infection, JAMA, 2003;290(22):2976–84.
    Crossref | PubMed
  15. Centers for Disease Control and Prevention. Vancomycinresistant Staphylococcus aureus: New York, 2004, MMWR Morb Mortal Wkly Rep, 2004;53(15):322–3.
    PubMed
  16. Whitener CJ, Park SY, Browne FA, et al., Vancomycinresistant Staphylococcus aureus in the absence of vancomycin exposure, Clin Infect Dis, 2004;38(8):1049–55.
    Crossref | PubMed
  17. Paul M, Silbiger I, Grozinsky S, et al., Beta lactam antibiotic monotherapy versus beta lactam, aminoglycoside antibiotic combination therapy for sepsis, Cochrane Database Syst Rev, 2006;CD003344.
    Crossref | PubMed
  18. Falagas ME, Matthaiou DK, Bliziotis IA, The role of aminoglycosides in combination with a beta-lactam for the treatment of bacterial endocarditis: a meta-analysis of comparative trials, J Antimicrob Chemother, 2006;57:639–47.
    Crossref | PubMed
  19. Baddour LM, Wilson WR, Bayer AS, et al., Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications, Circulation, 2005;14;111(23): e394–434.
    Crossref | PubMed
  20. Werner M, Andersson R, Olaison L, Hogevik H, Swedish Society of Infectious Diseases Quality Assurance Study Group for Endocarditis: A 10-year survey of blood culture negative endocarditis in Sweden: aminoglycoside therapy is important for survival, Scand J Infect Dis, 2008;40:279–85.
    Crossref | PubMed
  21. Fowler VG Jr, Boucher HW, Corey GR, et al., Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus, N Engl J Med, 2006;355(7): 653–65.
    Crossref | PubMed
  22. Falagas ME, Manta KG, Ntziora F, Vardakas KZ, Linezolid for the treatment of patients with endocarditis: a systematic review of the published evidence, J Antimicrob Chemother, 2006;58(2):273–80.
    Crossref | PubMed
  23. Wilson W, Taubert KA, Gewitz M, Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group, Circulation, 2007;116(15):1736–54.
    Crossref | PubMed
  24. Bonow RO, Carabello BA, Lytle BW, et al., ACC/AHA 2006 Guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Writing Committee to revise the 1998 guidelines for the management of patients with valvular heart disease) developed in collaboration with the society of cardiovascular anesthesiologists endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons, J Am Coll Cardiol, 2006;48:e1 - e148.
    Crossref | PubMed
  25. Vikram HR, Buenconsejo J, Hasbun R, Quagliarello VJ, Impact of valve surgery on 6-month mortality in adults with complicated, left-sided native valve endocarditis: a propensity analysis, JAMA, 2003;290(24):3207–14.
    Crossref | PubMed
  26. Vongpatanasin W, Hillis LD, Lange RA, Prosthetic heart valves, N Engl J Med, 1996;335:407–16.
    Crossref | PubMed
  27. Blackstone EH, Kirklin JW, Death and other time-related events after valve replacement, Circulation, 1985;72:753–67.
    Crossref | PubMed
  28. Wolff M, Witchitz S, Chastang C, et al., Prosthetic valve endocarditis in the ICU. Prognostic factors of overall survival in a series of 122 cases and consequences for treatment decision, Chest, 1995;108:688–94.
    Crossref | PubMed
  29. Tornos P, Almirante B, Olona M, et al., Clinical outcome and long-term prognosis of late prosthetic valve endocarditis: a 20-year experience, Clin Infect Dis, 1997;24:381–6.
    Crossref | PubMed
  30. Akowuah EF, Davies W, Oliver S, et al., Prosthetic valve endocarditis: early and late outcome following medical or surgical treatment, Heart, 2003;89:269–72.
    Crossref | PubMed
  31. Horstkotte D, Follath F, Gutschik E, et al., Guidelines on prevention, diagnosis and treatment of infective endocarditis executive summary; the task force on infective endocarditis of the European Society of Cardiology, Eur Heart J, 2004;25:267–76.
    Crossref | PubMed
  32. Tornos P, Iung B, Permanyer-Miralda G, et al., Infective endocarditis in Europe: lessons from the Euro heart survey, Heart, 2005;91:571–5.
    Crossref | PubMed